加入收藏 欢迎光临Abbkine Scientific Co., Ltd官方网站全国服务热线:400-6800-830
登录 注册
中文

亚科因(Abbkine)—服务于细胞和蛋白研究全球用户

货号 产品名称 文献标题 IF 杂志名称
KTE6017 EliKine™ 人白介素-6 ELISA定量试剂盒 Analysis of Serum Markers Under the Sandwich Elisa Method in Children Between 12 and 120 Months With Iron Deficiency Anemia in the City of Arequipa 2 HIV Nursing
KTE6017 EliKine™ 人白介素-6 ELISA定量试剂盒 Dietary sodium enhances the expression of SLC4 family transporters, IRBIT, L-IRBIT, and PP1 in rat kidney: Insights into the molecular mechanism for renal … 7 Antioxidants
KTE6018 EliKine™ 人白介素-8 ELISA定量试剂盒 Evaluation of cytotoxicity and anti-inflammatory action of AH-Plus sealer with and without petasin, pachymic acid, curcumin & shilajit: an invitro-study. 3.900 Scientific Reports 
KTE6019 EliKine™ 人白介素-10 ELISA定量试剂盒 Notch signaling pathway regulates the progression of fetal growth restriction through mediating immune dysfunction. 1.900 Biomedical Reports 
KTE6019 EliKine™ 人白介素-10 ELISA定量试剂盒 In vivo immunomodulatory effect and safety of MSC-derived secretome F1000Research
KTE6019 EliKine™ 人白介素-10 ELISA定量试剂盒 In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype. 4.700 International Immunopharmacology 
KTE6022 EliKine™ 人白介素-17 ELISA定量试剂盒 Notch signaling pathway regulates the progression of fetal growth restriction through mediating immune dysfunction. 1.900  Biomedical Reports 
KTE6022 EliKine™ 人白介素-17 ELISA定量试剂盒 In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype. 4.700 International Immunopharmacology
KTE6026 EliKine™ 人瘦素 ELISA定量试剂盒 Serum Biomarkers and Gene Polymorphisms in COPD and COPD with T2DM Patients. 2 Indian Journal of Clinical Biochemistry
KTE6027 EliKine™ 人基质金属蛋白酶-9 ELISA定量试剂盒 The association between APO-E genotype and inflammation and the risk of premature CHD in smokers versus non-smokers 2 Journal of Applied Pharmaceutical Science
意见反馈
在线咨询
扫码关注

微信公众号

返回顶部